 | • レポートコード：MRC2-11QY02583 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗肥満処方のグローバル市場について調査・分析したレポートです。種類別（ブプロピオン・ナルトレキソン、オルリスタット、ロカセリン、フェンテルミン・トピラマート、リラグルチド）市場規模、用途別（病院薬局、小売薬局、Eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗肥満処方の競争状況、市場シェア ・世界の抗肥満処方市場：種類別市場規模 2015年-2020年（ブプロピオン・ナルトレキソン、オルリスタット、ロカセリン、フェンテルミン・トピラマート、リラグルチド） ・世界の抗肥満処方市場：種類別市場規模予測 2021年-2026年（ブプロピオン・ナルトレキソン、オルリスタット、ロカセリン、フェンテルミン・トピラマート、リラグルチド） ・世界の抗肥満処方市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、Eコマース） ・世界の抗肥満処方市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、Eコマース） ・北米の抗肥満処方市場分析：米国、カナダ ・ヨーロッパの抗肥満処方市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗肥満処方市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗肥満処方市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗肥満処方市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Zydus Cadila、Akrimax Pharmaceuticals、Zealand Pharma、Arrowhead Research、Arena Pharmaceuticals、Compellis Pharmaceuticals、Yungjin Pharm、Alpex Pharma、Bridge BioResearch ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.
There is increased use of anti-obesity prescription due to increasing obesity endemic. Sedentary lifestyle and junk food habits, increasing healthcare expenditure and rise in aging population are some of the key factors driving the growth for global anti-obesity prescription market. In addition, increasing healthcare awareness is also fuelling the growth of the global anti-obesity prescription market. However, side effects of anti-obesity drugs, high drug development cost and strict regulatory framework are some of the major factors restraining the growth for the global anti-obesity prescription market.
Market Analysis and Insights: Global Anti-Obesity Prescription Market
The global Anti-Obesity Prescription market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anti-Obesity Prescription Scope and Market Size
Anti-Obesity Prescription market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Obesity Prescription market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-Obesity Prescription market is segmented into
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Segment by Application, the Anti-Obesity Prescription market is segmented into
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Regional and Country-level Analysis
The Anti-Obesity Prescription market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-Obesity Prescription market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anti-Obesity Prescription Market Share Analysis
Anti-Obesity Prescription market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Obesity Prescription business, the date to enter into the Anti-Obesity Prescription market, Anti-Obesity Prescription product introduction, recent developments, etc.
The major vendors covered:
Zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma
Bridge BioResearch
1 Study Coverage
1.1 Anti-Obesity Prescription Product Introduction
1.2 Market Segments
1.3 Key Anti-Obesity Prescription Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-Obesity Prescription Market Size Growth Rate by Type
1.4.2 Bupropion and Naltrexone
1.4.3 Orlistat
1.4.4 Lorcaserin
1.4.5 Phentermine and Topiramate
1.4.6 Liraglutide
1.5 Market by Application
1.5.1 Global Anti-Obesity Prescription Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 E-Commerce
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-Obesity Prescription Market Size, Estimates and Forecasts
2.1.1 Global Anti-Obesity Prescription Revenue 2015-2026
2.1.2 Global Anti-Obesity Prescription Sales 2015-2026
2.2 Global Anti-Obesity Prescription, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-Obesity Prescription Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-Obesity Prescription Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-Obesity Prescription Competitor Landscape by Players
3.1 Anti-Obesity Prescription Sales by Manufacturers
3.1.1 Anti-Obesity Prescription Sales by Manufacturers (2015-2020)
3.1.2 Anti-Obesity Prescription Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-Obesity Prescription Revenue by Manufacturers
3.2.1 Anti-Obesity Prescription Revenue by Manufacturers (2015-2020)
3.2.2 Anti-Obesity Prescription Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-Obesity Prescription Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-Obesity Prescription Revenue in 2019
3.2.5 Global Anti-Obesity Prescription Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-Obesity Prescription Price by Manufacturers
3.4 Anti-Obesity Prescription Manufacturing Base Distribution, Product Types
3.4.1 Anti-Obesity Prescription Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-Obesity Prescription Product Type
3.4.3 Date of International Manufacturers Enter into Anti-Obesity Prescription Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-Obesity Prescription Market Size by Type (2015-2020)
4.1.1 Global Anti-Obesity Prescription Sales by Type (2015-2020)
4.1.2 Global Anti-Obesity Prescription Revenue by Type (2015-2020)
4.1.3 Anti-Obesity Prescription Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-Obesity Prescription Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-Obesity Prescription Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-Obesity Prescription Revenue Forecast by Type (2021-2026)
4.2.3 Anti-Obesity Prescription Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-Obesity Prescription Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-Obesity Prescription Market Size by Application (2015-2020)
5.1.1 Global Anti-Obesity Prescription Sales by Application (2015-2020)
5.1.2 Global Anti-Obesity Prescription Revenue by Application (2015-2020)
5.1.3 Anti-Obesity Prescription Price by Application (2015-2020)
5.2 Anti-Obesity Prescription Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-Obesity Prescription Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-Obesity Prescription Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-Obesity Prescription Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-Obesity Prescription by Country
6.1.1 North America Anti-Obesity Prescription Sales by Country
6.1.2 North America Anti-Obesity Prescription Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-Obesity Prescription Market Facts & Figures by Type
6.3 North America Anti-Obesity Prescription Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-Obesity Prescription by Country
7.1.1 Europe Anti-Obesity Prescription Sales by Country
7.1.2 Europe Anti-Obesity Prescription Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-Obesity Prescription Market Facts & Figures by Type
7.3 Europe Anti-Obesity Prescription Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-Obesity Prescription by Region
8.1.1 Asia Pacific Anti-Obesity Prescription Sales by Region
8.1.2 Asia Pacific Anti-Obesity Prescription Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-Obesity Prescription Market Facts & Figures by Type
8.3 Asia Pacific Anti-Obesity Prescription Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-Obesity Prescription by Country
9.1.1 Latin America Anti-Obesity Prescription Sales by Country
9.1.2 Latin America Anti-Obesity Prescription Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-Obesity Prescription Market Facts & Figures by Type
9.3 Central & South America Anti-Obesity Prescription Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-Obesity Prescription by Country
10.1.1 Middle East and Africa Anti-Obesity Prescription Sales by Country
10.1.2 Middle East and Africa Anti-Obesity Prescription Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-Obesity Prescription Market Facts & Figures by Type
10.3 Middle East and Africa Anti-Obesity Prescription Market Facts & Figures by Application
11 Company Profiles
11.1 Zydus Cadila
11.1.1 Zydus Cadila Corporation Information
11.1.2 Zydus Cadila Description and Business Overview
11.1.3 Zydus Cadila Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Zydus Cadila Anti-Obesity Prescription Products Offered
11.1.5 Zydus Cadila Related Developments
11.2 Akrimax Pharmaceuticals
11.2.1 Akrimax Pharmaceuticals Corporation Information
11.2.2 Akrimax Pharmaceuticals Description and Business Overview
11.2.3 Akrimax Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Products Offered
11.2.5 Akrimax Pharmaceuticals Related Developments
11.3 Zealand Pharma
11.3.1 Zealand Pharma Corporation Information
11.3.2 Zealand Pharma Description and Business Overview
11.3.3 Zealand Pharma Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Zealand Pharma Anti-Obesity Prescription Products Offered
11.3.5 Zealand Pharma Related Developments
11.4 Arrowhead Research
11.4.1 Arrowhead Research Corporation Information
11.4.2 Arrowhead Research Description and Business Overview
11.4.3 Arrowhead Research Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Arrowhead Research Anti-Obesity Prescription Products Offered
11.4.5 Arrowhead Research Related Developments
11.5 Arena Pharmaceuticals
11.5.1 Arena Pharmaceuticals Corporation Information
11.5.2 Arena Pharmaceuticals Description and Business Overview
11.5.3 Arena Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Arena Pharmaceuticals Anti-Obesity Prescription Products Offered
11.5.5 Arena Pharmaceuticals Related Developments
11.6 Compellis Pharmaceuticals
11.6.1 Compellis Pharmaceuticals Corporation Information
11.6.2 Compellis Pharmaceuticals Description and Business Overview
11.6.3 Compellis Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Products Offered
11.6.5 Compellis Pharmaceuticals Related Developments
11.7 Yungjin Pharm
11.7.1 Yungjin Pharm Corporation Information
11.7.2 Yungjin Pharm Description and Business Overview
11.7.3 Yungjin Pharm Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Yungjin Pharm Anti-Obesity Prescription Products Offered
11.7.5 Yungjin Pharm Related Developments
11.8 Alpex Pharma
11.8.1 Alpex Pharma Corporation Information
11.8.2 Alpex Pharma Description and Business Overview
11.8.3 Alpex Pharma Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Alpex Pharma Anti-Obesity Prescription Products Offered
11.8.5 Alpex Pharma Related Developments
11.9 Bridge BioResearch
11.9.1 Bridge BioResearch Corporation Information
11.9.2 Bridge BioResearch Description and Business Overview
11.9.3 Bridge BioResearch Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Bridge BioResearch Anti-Obesity Prescription Products Offered
11.9.5 Bridge BioResearch Related Developments
11.1 Zydus Cadila
11.1.1 Zydus Cadila Corporation Information
11.1.2 Zydus Cadila Description and Business Overview
11.1.3 Zydus Cadila Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Zydus Cadila Anti-Obesity Prescription Products Offered
11.1.5 Zydus Cadila Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-Obesity Prescription Market Estimates and Projections by Region
12.1.1 Global Anti-Obesity Prescription Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-Obesity Prescription Revenue Forecast by Regions 2021-2026
12.2 North America Anti-Obesity Prescription Market Size Forecast (2021-2026)
12.2.1 North America: Anti-Obesity Prescription Sales Forecast (2021-2026)
12.2.2 North America: Anti-Obesity Prescription Revenue Forecast (2021-2026)
12.2.3 North America: Anti-Obesity Prescription Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-Obesity Prescription Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-Obesity Prescription Sales Forecast (2021-2026)
12.3.2 Europe: Anti-Obesity Prescription Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-Obesity Prescription Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-Obesity Prescription Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-Obesity Prescription Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-Obesity Prescription Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-Obesity Prescription Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-Obesity Prescription Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-Obesity Prescription Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-Obesity Prescription Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-Obesity Prescription Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-Obesity Prescription Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-Obesity Prescription Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-Obesity Prescription Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-Obesity Prescription Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anti-Obesity Prescription Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-Obesity Prescription Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Anti-Obesity Prescription Market Segments
Table 2. Ranking of Global Top Anti-Obesity Prescription Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anti-Obesity Prescription Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Bupropion and Naltrexone
Table 5. Major Manufacturers of Orlistat
Table 6. Major Manufacturers of Lorcaserin
Table 7. Major Manufacturers of Phentermine and Topiramate
Table 8. Major Manufacturers of Liraglutide
Table 9. Global Anti-Obesity Prescription Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Anti-Obesity Prescription Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Anti-Obesity Prescription Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Anti-Obesity Prescription Sales Market Share by Regions (2015-2020)
Table 13. Global Anti-Obesity Prescription Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Anti-Obesity Prescription Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Anti-Obesity Prescription Sales Share by Manufacturers (2015-2020)
Table 16. Global Anti-Obesity Prescription Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Anti-Obesity Prescription by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Prescription as of 2019)
Table 18. Anti-Obesity Prescription Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Anti-Obesity Prescription Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Anti-Obesity Prescription Price (2015-2020) (USD/Pcs)
Table 21. Anti-Obesity Prescription Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Anti-Obesity Prescription Product Type
Table 23. Date of International Manufacturers Enter into Anti-Obesity Prescription Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Anti-Obesity Prescription Sales by Type (2015-2020) (K Pcs)
Table 26. Global Anti-Obesity Prescription Sales Share by Type (2015-2020)
Table 27. Global Anti-Obesity Prescription Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Anti-Obesity Prescription Revenue Share by Type (2015-2020)
Table 29. Anti-Obesity Prescription Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Anti-Obesity Prescription Sales by Application (2015-2020) (K Pcs)
Table 31. Global Anti-Obesity Prescription Sales Share by Application (2015-2020)
Table 32. North America Anti-Obesity Prescription Sales by Country (2015-2020) (K Pcs)
Table 33. North America Anti-Obesity Prescription Sales Market Share by Country (2015-2020)
Table 34. North America Anti-Obesity Prescription Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Anti-Obesity Prescription Revenue Market Share by Country (2015-2020)
Table 36. North America Anti-Obesity Prescription Sales by Type (2015-2020) (K Pcs)
Table 37. North America Anti-Obesity Prescription Sales Market Share by Type (2015-2020)
Table 38. North America Anti-Obesity Prescription Sales by Application (2015-2020) (K Pcs)
Table 39. North America Anti-Obesity Prescription Sales Market Share by Application (2015-2020)
Table 40. Europe Anti-Obesity Prescription Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Anti-Obesity Prescription Sales Market Share by Country (2015-2020)
Table 42. Europe Anti-Obesity Prescription Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Anti-Obesity Prescription Revenue Market Share by Country (2015-2020)
Table 44. Europe Anti-Obesity Prescription Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Anti-Obesity Prescription Sales Market Share by Type (2015-2020)
Table 46. Europe Anti-Obesity Prescription Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Anti-Obesity Prescription Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Anti-Obesity Prescription Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Anti-Obesity Prescription Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Anti-Obesity Prescription Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Anti-Obesity Prescription Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Anti-Obesity Prescription Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Anti-Obesity Prescription Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Anti-Obesity Prescription Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Anti-Obesity Prescription Sales Market Share by Application (2015-2020)
Table 56. Latin America Anti-Obesity Prescription Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Anti-Obesity Prescription Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Anti-Obesity Prescription Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Anti-Obesity Prescription Revenue Market Share by Country (2015-2020)
Table 60. Latin America Anti-Obesity Prescription Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Anti-Obesity Prescription Sales Market Share by Type (2015-2020)
Table 62. Latin America Anti-Obesity Prescription Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Anti-Obesity Prescription Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Anti-Obesity Prescription Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Anti-Obesity Prescription Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Anti-Obesity Prescription Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Anti-Obesity Prescription Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Anti-Obesity Prescription Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Anti-Obesity Prescription Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Anti-Obesity Prescription Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Anti-Obesity Prescription Sales Market Share by Application (2015-2020)
Table 72. Zydus Cadila Corporation Information
Table 73. Zydus Cadila Description and Major Businesses
Table 74. Zydus Cadila Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Zydus Cadila Product
Table 76. Zydus Cadila Recent Development
Table 77. Akrimax Pharmaceuticals Corporation Information
Table 78. Akrimax Pharmaceuticals Description and Major Businesses
Table 79. Akrimax Pharmaceuticals Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Akrimax Pharmaceuticals Product
Table 81. Akrimax Pharmaceuticals Recent Development
Table 82. Zealand Pharma Corporation Information
Table 83. Zealand Pharma Description and Major Businesses
Table 84. Zealand Pharma Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Zealand Pharma Product
Table 86. Zealand Pharma Recent Development
Table 87. Arrowhead Research Corporation Information
Table 88. Arrowhead Research Description and Major Businesses
Table 89. Arrowhead Research Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Arrowhead Research Product
Table 91. Arrowhead Research Recent Development
Table 92. Arena Pharmaceuticals Corporation Information
Table 93. Arena Pharmaceuticals Description and Major Businesses
Table 94. Arena Pharmaceuticals Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Arena Pharmaceuticals Product
Table 96. Arena Pharmaceuticals Recent Development
Table 97. Compellis Pharmaceuticals Corporation Information
Table 98. Compellis Pharmaceuticals Description and Major Businesses
Table 99. Compellis Pharmaceuticals Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Compellis Pharmaceuticals Product
Table 101. Compellis Pharmaceuticals Recent Development
Table 102. Yungjin Pharm Corporation Information
Table 103. Yungjin Pharm Description and Major Businesses
Table 104. Yungjin Pharm Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Yungjin Pharm Product
Table 106. Yungjin Pharm Recent Development
Table 107. Alpex Pharma Corporation Information
Table 108. Alpex Pharma Description and Major Businesses
Table 109. Alpex Pharma Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Alpex Pharma Product
Table 111. Alpex Pharma Recent Development
Table 112. Bridge BioResearch Corporation Information
Table 113. Bridge BioResearch Description and Major Businesses
Table 114. Bridge BioResearch Anti-Obesity Prescription Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Bridge BioResearch Product
Table 116. Bridge BioResearch Recent Development
Table 117. Global Anti-Obesity Prescription Sales Forecast by Regions (2021-2026) (K Pcs)
Table 118. Global Anti-Obesity Prescription Sales Market Share Forecast by Regions (2021-2026)
Table 119. Global Anti-Obesity Prescription Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 120. Global Anti-Obesity Prescription Revenue Market Share Forecast by Regions (2021-2026)
Table 121. North America: Anti-Obesity Prescription Sales Forecast by Country (2021-2026) (K Pcs)
Table 122. North America: Anti-Obesity Prescription Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Europe: Anti-Obesity Prescription Sales Forecast by Country (2021-2026) (K Pcs)
Table 124. Europe: Anti-Obesity Prescription Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Asia Pacific: Anti-Obesity Prescription Sales Forecast by Region (2021-2026) (K Pcs)
Table 126. Asia Pacific: Anti-Obesity Prescription Revenue Forecast by Region (2021-2026) (US$ Million)
Table 127. Latin America: Anti-Obesity Prescription Sales Forecast by Country (2021-2026) (K Pcs)
Table 128. Latin America: Anti-Obesity Prescription Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Middle East and Africa: Anti-Obesity Prescription Sales Forecast by Country (2021-2026) (K Pcs)
Table 130. Middle East and Africa: Anti-Obesity Prescription Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 132. Key Challenges
Table 133. Market Risks
Table 134. Main Points Interviewed from Key Anti-Obesity Prescription Players
Table 135. Anti-Obesity Prescription Customers List
Table 136. Anti-Obesity Prescription Distributors List
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Obesity Prescription Product Picture
Figure 2. Global Anti-Obesity Prescription Sales Market Share by Type in 2020 & 2026
Figure 3. Bupropion and Naltrexone Product Picture
Figure 4. Orlistat Product Picture
Figure 5. Lorcaserin Product Picture
Figure 6. Phentermine and Topiramate Product Picture
Figure 7. Liraglutide Product Picture
Figure 8. Global Anti-Obesity Prescription Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. E-Commerce
Figure 12. Anti-Obesity Prescription Report Years Considered
Figure 13. Global Anti-Obesity Prescription Market Size 2015-2026 (US$ Million)
Figure 14. Global Anti-Obesity Prescription Sales 2015-2026 (K Pcs)
Figure 15. Global Anti-Obesity Prescription Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Anti-Obesity Prescription Sales Market Share by Region (2015-2020)
Figure 17. Global Anti-Obesity Prescription Sales Market Share by Region in 2019
Figure 18. Global Anti-Obesity Prescription Revenue Market Share by Region (2015-2020)
Figure 19. Global Anti-Obesity Prescription Revenue Market Share by Region in 2019
Figure 20. Global Anti-Obesity Prescription Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Anti-Obesity Prescription Revenue in 2019
Figure 22. Anti-Obesity Prescription Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Anti-Obesity Prescription Sales Market Share by Type (2015-2020)
Figure 24. Global Anti-Obesity Prescription Sales Market Share by Type in 2019
Figure 25. Global Anti-Obesity Prescription Revenue Market Share by Type (2015-2020)
Figure 26. Global Anti-Obesity Prescription Revenue Market Share by Type in 2019
Figure 27. Global Anti-Obesity Prescription Market Share by Price Range (2015-2020)
Figure 28. Global Anti-Obesity Prescription Sales Market Share by Application (2015-2020)
Figure 29. Global Anti-Obesity Prescription Sales Market Share by Application in 2019
Figure 30. Global Anti-Obesity Prescription Revenue Market Share by Application (2015-2020)
Figure 31. Global Anti-Obesity Prescription Revenue Market Share by Application in 2019
Figure 32. North America Anti-Obesity Prescription Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Anti-Obesity Prescription Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Anti-Obesity Prescription Sales Market Share by Country in 2019
Figure 35. North America Anti-Obesity Prescription Revenue Market Share by Country in 2019
Figure 36. U.S. Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Anti-Obesity Prescription Market Share by Type in 2019
Figure 41. North America Anti-Obesity Prescription Market Share by Application in 2019
Figure 42. Europe Anti-Obesity Prescription Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Anti-Obesity Prescription Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Anti-Obesity Prescription Sales Market Share by Country in 2019
Figure 45. Europe Anti-Obesity Prescription Revenue Market Share by Country in 2019
Figure 46. Germany Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Anti-Obesity Prescription Market Share by Type in 2019
Figure 57. Europe Anti-Obesity Prescription Market Share by Application in 2019
Figure 58. Asia Pacific Anti-Obesity Prescription Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Anti-Obesity Prescription Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Anti-Obesity Prescription Sales Market Share by Region in 2019
Figure 61. Asia Pacific Anti-Obesity Prescription Revenue Market Share by Region in 2019
Figure 62. China Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Anti-Obesity Prescription Market Share by Type in 2019
Figure 85. Asia Pacific Anti-Obesity Prescription Market Share by Application in 2019
Figure 86. Latin America Anti-Obesity Prescription Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Anti-Obesity Prescription Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Anti-Obesity Prescription Sales Market Share by Country in 2019
Figure 89. Latin America Anti-Obesity Prescription Revenue Market Share by Country in 2019
Figure 90. Mexico Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Anti-Obesity Prescription Market Share by Type in 2019
Figure 97. Latin America Anti-Obesity Prescription Market Share by Application in 2019
Figure 98. Middle East and Africa Anti-Obesity Prescription Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Anti-Obesity Prescription Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Anti-Obesity Prescription Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Anti-Obesity Prescription Revenue Market Share by Country in 2019
Figure 102. Turkey Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Anti-Obesity Prescription Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Anti-Obesity Prescription Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Anti-Obesity Prescription Market Share by Type in 2019
Figure 109. Middle East and Africa Anti-Obesity Prescription Market Share by Application in 2019
Figure 110. North America Anti-Obesity Prescription Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Anti-Obesity Prescription Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Anti-Obesity Prescription Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Anti-Obesity Prescription Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Anti-Obesity Prescription Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Anti-Obesity Prescription Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Anti-Obesity Prescription Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Anti-Obesity Prescription Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Anti-Obesity Prescription Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Anti-Obesity Prescription Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
抗肥満薬（抗肥満薬）の世界市場（～2026年） Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. Market Analysis and Insights: Global Ant…- 抗肥満薬の世界市場（～2026年） Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain diet…
- 抗肥満療法の世界市場（～2026年） Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways. Geographically, North America captures the largest …
- 処方用皮膚科薬の世界市場（～2026年） Market Analysis and Insights: Global Prescription Dermatological Drugs Market The global Prescription Dermatological Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Prescription Dermatological Drugs Scope and Mar…
- 肥満管理の世界市場（～2026年） Lifestyle diseases such as diabetes and other chronic ailments are the main cause of obesity around the world. Improved healthcare and medical facilities have led to an increase in the life expectancy of people, which is the primary reason for the large geriatric population seen in the developed wor…